The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Expansion In Market Value Is Forecasted For The Gestational Trophoblastic Disease Market Between 2026 And 2030?
The gestational trophoblastic disease market has seen consistent expansion over recent years. Forecasting its continued expansion, the market is projected to rise from $2.16 billion in 2025 to $2.26 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.6%. This historical growth was primarily driven by several factors, including developments in gynecologic oncology, the widespread availability of hCG testing, the adoption of surgical treatments, heightened awareness regarding rare pregnancy disorders, and established clinical oncology protocols.
The gestational trophoblastic disease market is projected to experience robust expansion in the coming years. This market is set to reach $2.81 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. This anticipated growth during the forecast period is primarily driven by factors such as enhanced diagnostic precision, the proliferation of oncology facilities, the establishment of uniform treatment protocols, wider access to healthcare services, and a heightened emphasis on managing rare diseases. Key trends anticipated for the forecast timeframe encompass advancements in hCG-based disease tracking, an increasing adoption of chemotherapy in GTD management, a greater emphasis on early detection, the expansion of specialized women’s oncology care, and more effective post-treatment follow-up.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Primary Drivers Are Impacting The Gestational Trophoblastic Disease Market Growth?
The increasing rates of infertility are projected to drive the expansion of the gestational trophoblastic disease market. Infertility rates denote the proportion of couples or individuals unable to conceive naturally after a year of regular, unprotected sexual activity. These rising rates are largely attributable to advanced maternal and paternal age, which is linked to diminished egg and sperm quality, reduced fertility, and elevated risks of conception complications. Intriguingly, gestational trophoblastic disease, despite being a pathological state, can offer insights into infertility treatments by highlighting the role of trophoblastic tissue in implantation and hormonal regulation, thereby guiding interventions to enhance conception success. For example, in April 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately 17.5% of adults, or about 1 in 6 people globally, experience infertility, underscoring the critical need to improve access to affordable, high-quality fertility care for those affected. Consequently, the escalating infertility rates are propelling the gestational trophoblastic disease market. The growing trend of cigarette smoking is anticipated to fuel the growth of the gestational trophoblastic disease market in the future. Cigarette smoking involves igniting tobacco and inhaling the resultant smoke, which contains various chemicals and toxins detrimental to different bodily structures. Smoking has the potential to damage the DNA of trophoblastic cells, which are crucial for placenta formation, possibly leading to abnormal cell growth and division, and subsequently gestational trophoblastic disease. For instance, in October 2024, a study on youth smoking trends, conducted by the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, indicated a substantial increase in smoking rates, with 40.1% of respondents smoking in 2024 compared to 22.5% in 2022. Therefore, the rise in cigarette smoking is a key driver for the gestational trophoblastic disease market.
How Are Different Segments Classified In The Gestational Trophoblastic Disease Market Segment Analysis?
The gestational trophoblastic disease market covered in this report is segmented –
1) By Type: Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor, Other Types
2) By Treatment: Surgery, Chemotherapy, Suction Dilation And Curettage (D&C), Radiation Therapy
3) By End User: Hospital And Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Hydatidiform Mole: Complete Hydatidiform Mole, Partial Hydatidiform Mole
2) By Choriocarcinoma: Non-Metastatic Choriocarcinoma, Metastatic Choriocarcinoma
3) By Placental-Site Trophoblastic Tumor: PSTT With Normal Placentation, PSTT With Abnormal Placentation
4) By Epithelioid Trophoblastic Tumor: Epithelioid Trophoblastic Tumor With No Evidence Of Metastasis, Epithelioid Trophoblastic Tumor With Metastasis
5) By Other Types: Trophoblastic Tumor Of Unknown Origin, Non-Gestational Trophoblastic Neoplasia
Who Are The Companies Driving Activity In The Gestational Trophoblastic Disease Market?
Major companies operating in the gestational trophoblastic disease market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd.
Get The Full Gestational Trophoblastic Disease Market Report:
Which Region Accounts For The Largest Portion Of The Gestational Trophoblastic Disease Market?
Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Gestational Trophoblastic Disease Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Gestational Trophoblastic Disease Market 2026, By The Business Research Company
Human Chorionic Gonadotropin Market Report 2026
https://www.thebusinessresearchcompany.com/report/human-chorionic-gonadotropin-global-market-report
Pompe Disease Market Report 2026
https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report
Ectopic Pregnancy Market Report 2026
https://www.thebusinessresearchcompany.com/report/ectopic-pregnancy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model